Letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive platinum-resistant recurrent epithelial ovarian cancer patients following second-line platinum-based chemotherapy failure: A prospective, single-arm, open-label, phase II study

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 997cf282dc7667d1-IAD IP: 118.31.43.22 UTC time: 2025-11-01T17:00:15+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4

View original article

GYNECOLOGIC ONCOLOGY

Like

Share Bookmark

0 0 0 0 0 0 0

More from this channel

Letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive platinum-resistant recurrent epithelial ovarian cancer patients following second-line platinum-based chemotherapy failure: A prospective, single-arm, open-label, phase II study

Comments (0)